Endometrial cancer is rising in both incidence and mortality globally. Improved understanding of endometrial cancer through molecular profiling has identified different molecular alterations that may have implications both in the adjuvant and advanced setting. Data from recent trials involving immunotherapy combinations or antibody drug conjugates will be presented.